A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
September 11, 2026
A Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior Therapies